Peptides Representing Genus-Specific Chlamydial Antigens for Vaccine Peptide Vaccines for Chlamydia to be Delivered Orally or by Other Mucosal Routes

Case ID:


Despite increased surveillance and treatment, sexually transmitted disease infections caused by Chlamydia continue to rise. It is estimated that over 20 million new cases of infection occur annually in developed countries, with over 75 million new cases occurring annually in developing countries.  Chlamydial genital tract infection is more than 5 times more common than gonorrhea and has been correlated with increased risk of HIV infection and other STD pathogens. Chlamydia trachomatis is the leading cause of tubal infertility and pelvic inflammatory disease.   Chlamydial genital infection occurs in 5-15% of pregnant women, and 50% of their babies will develop inclusion conjunctivitis or respiratory infections making C. trachomatis the most common ocular pathogen in infants.  40% of those infected who are left untreated experience pelvic inflammatory disease with permanent damage, chronic pain, infertility and potentially fatal pregnancies.   Other factors such as repeated exposure, asymptomatic and/or persistent infections make diagnosis difficult, which leads authorities to estimate that the number of infected individuals is double the number of reported infections.  Although antibiotics can clear many chlamydial infections, they do not prevent re-infection.


Wayne State University inventors have developed several peptide vaccine candidates that are genus specific; conformational; and easy to manufacture. These benefits overcome several of the prior impediments to the development of a Chlamydia vaccine: antigenically diverse surface proteins; enhanced survival within host cells; biphasic development cycle; reduced inflammatory responses; and the ability to enter a persistent state. New research results include antibody responses of peptide-immunized mice against individual peptides; reduction in infectious loads and gross inflammation (histology in progress); adoptive transfer of spleen cells from immunized BALB/c mice to SCID or naïve BALB/c mice which were subsequently challenged with C. trachomatis showing protection (histology, infectious loads). Additional challenge studies are being done.

Patent Status:   A PCT patent application is pending.

Licensing Terms:  An exclusive licensing arrangement is desired.  Discussions regarding compassionate use and distribution in developing countries are necessary.

Patent Information:
For Information, Contact:
Joan Dunbar
Associate Vice President for Technology Commercialization
Wayne State University
(313) 577-5542
Judith WhittuM-Hudson
Alan Hudson